Reference
1. Andersen AN, Gianaroli L,
Felberbaum R, et al. Assisted reproductive technology in Europe, 2001.
Results generated from European registers by ESHRE. Human
reproduction (Oxford, England) 2005;20(5):1158-76.
2. Olivennes F, Belaisch-Allart J,
Emperaire J-C, et al. Prospective, randomized, controlled study of in
vitro fertilization-embryo transfer with a single dose of a luteinizing
hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot
formula of an LH-RH agonist (triptorelin). Fertility and
sterility 2000;73(2):314-20.
3. Westergaard LG, Erb K, Laursen SB,
et al. Human menopausal gonadotropin versus recombinant
follicle-stimulating hormone in normogonadotropic women down-regulated
with a gonadotropin-releasing hormone agonist who were undergoing in
vitro fertilization and intracytoplasmic sperm injection: a prospective
randomized study. Fertility and sterility 2001;76(3):543-9. doi:
10.1016/s0015-0282(01)01973-2 [published Online First: 2001/09/05]
4. Younis JS. ”Premature
luteinization” in the era of GnRH analogue protocols: time to
reconsider. Journal of assisted reproduction and genetics2011;28(8):689-92. doi: 10.1007/s10815-011-9585-x [published Online
First: 2011/05/27]
5. Pelinck MJ, Hoek A, Simons AH, et
al. Efficacy of natural cycle IVF: a review of the literature.Human reproduction update 2002;8(2):129-39. doi:
10.1093/humupd/8.2.129 [published Online First: 2002/07/09]
6. Smacklon N, Fauser BC. Regulation
of follicle development and novel approaches to ovarian stimulation for
IVF. Human reproduction update 2000;6(4):307-12. doi:
10.1093/humupd/6.4.307 [published Online First: 2000/09/06]
7. van Tilborg TC, Broekmans FJ.
Individualized follicle-stimulating hormone dosing and in vitro
fertilization outcome in agonist downregulated cycles: a systematic
review. 2016;95(12):1333-44. doi: 10.1111/aogs.13032
8. Van Tilborg TC, Torrance HL,
Oudshoorn SC, et al. Individualized versus standard FSH dosing in women
starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.Human Reproduction 2017;32(12):2496-505.
9. Toftager M, Bogstad J, Bryndorf T,
et al. Risk of severe ovarian hyperstimulation syndrome in GnRH
antagonist versus GnRH agonist protocol: RCT including 1050 first
IVF/ICSI cycles. Human reproduction (Oxford, England)2016;31(6):1253-64. doi: 10.1093/humrep/dew051 [published Online
First: 2016/04/10]
10. Kuang Y, Chen Q, Fu Y, et al.
Medroxyprogesterone acetate is an effective oral alternative for
preventing premature luteinizing hormone surges in women undergoing
controlled ovarian hyperstimulation for in vitro fertilization.Fertility and sterility 2015;104(1):62-70.e3. doi:
10.1016/j.fertnstert.2015.03.022 [published Online First:
2015/05/10]
11. Wang Y, Chen Q, Wang N, et al.
Controlled ovarian stimulation using medroxyprogesterone acetate and hMG
in patients with polycystic ovary syndrome treated for IVF: a
double-blind randomized crossover clinical trial. Medicine2016;95(9)
12. Zhu X, Zhang X, Fu Y. Utrogestan
as an effective oral alternative for preventing premature luteinizing
hormone surges in women undergoing controlled ovarian hyperstimulation
for in vitro fertilization. Medicine 2015;94(21):e909. doi:
10.1097/md.0000000000000909 [published Online First: 2015/05/29]
13. Zhu X, Ye H, Fu Y. The Utrogestan
and hMG protocol in patients with polycystic ovarian syndrome undergoing
controlled ovarian hyperstimulation during IVF/ICSI treatments.Medicine 2016;95(28):e4193. doi: 10.1097/md.0000000000004193
[published Online First: 2016/07/20]
14. Zhu X, Ye H, Fu Y. Use of
Utrogestan during controlled ovarian hyperstimulation in normally
ovulating women undergoing in vitro fertilization or intracytoplasmic
sperm injection treatments in combination with a ”freeze all” strategy:
a randomized controlled dose-finding study of 100 mg versus 200 mg.Fertility and sterility 2017;107(2):379-86.e4. doi:
10.1016/j.fertnstert.2016.10.030 [published Online First:
2016/11/21]
15. Zhu X, Ye H, Fu Y. Duphaston and
human menopausal gonadotropin protocol in normally ovulatory women
undergoing controlled ovarian hyperstimulation during in vitro
fertilization/intracytoplasmic sperm injection treatments in combination
with embryo cryopreservation. Fertility and sterility2017;108(3):505-12.e2. doi: 10.1016/j.fertnstert.2017.06.017
[published Online First: 2017/07/13]
16. Dong J, Wang Y, Chai WR, et al.
The pregnancy outcome of progestin-primed ovarian stimulation using 4
versus 10 mg of medroxyprogesterone acetate per day in infertile women
undergoing in vitro fertilisation: a randomised controlled trial.BJOG : an international journal of obstetrics and gynaecology2017;124(7):1048-55. doi: 10.1111/1471-0528.14622 [published Online
First: 2017/03/10]
17. Yu S, Long H, Chang HY, et al.
New application of dydrogesterone as a part of a progestin-primed
ovarian stimulation protocol for IVF: a randomized controlled trial
including 516 first IVF/ICSI cycles. Human reproduction (Oxford,
England) 2018;33(2):229-37. doi: 10.1093/humrep/dex367 [published
Online First: 2018/01/05]
18. Luke B, Brown MB, Wantman E, et
al. Cumulative birth rates with linked assisted reproductive technology
cycles. The New England journal of medicine 2012;366(26):2483-91.
doi: 10.1056/NEJMoa1110238 [published Online First: 2012/06/29]
19. Maheshwari A, McLernon D,
Bhattacharya S. Cumulative live birth rate: time for a consensus?Human reproduction (Oxford, England) 2015;30(12):2703-7. doi:
10.1093/humrep/dev263 [published Online First: 2015/10/16]
20. De Neubourg D, Bogaerts K,
Blockeel C, et al. How do cumulative live birth rates and cumulative
multiple live birth rates over complete courses of assisted reproductive
technology treatment per woman compare among registries? Human
reproduction (Oxford, England) 2016;31(1):93-9. doi:
10.1093/humrep/dev270 [published Online First: 2015/11/06]
21. McLernon DJ, Maheshwari A, Lee
AJ, et al. Cumulative live birth rates after one or more complete cycles
of IVF: a population-based study of linked cycle data from 178,898
women. Human reproduction (Oxford, England) 2016;31(3):572-81.
doi: 10.1093/humrep/dev336 [published Online First: 2016/01/20]
22. SOULES MR, STEINER RA, CLIFTON
DK, et al. Progesterone Modulation of Pulsatile Luteinizing Hormone
Secretion in Normal Women*. The Journal of Clinical Endocrinology
& Metabolism 1984;58(2):378-83. doi: 10.1210/jcem-58-2-378
23. Chabbert-Buffeta N, Skinner DC,
Caraty A, et al. Neuroendocrine effects of progesterone. Steroids2000;65(10):613-20. doi:https://doi.org/10.1016/S0039-128X(00)00187-2
24. Xu B, Geerts D, Hu S, et al. The
depot GnRH agonist protocol improves the live birth rate per fresh
embryo transfer cycle, but not the cumulative live birth rate in normal
responders: a randomized controlled trial and molecular mechanism study.Human Reproduction 2020;35(6):1306-18.
25. Lu X, Chen Q, Fu Y, et al.
Elevated progesterone on the trigger day does not impair the outcome of
Human Menotrophins Gonadotrophin and Medroxyprogesterone acetate
treatment cycles. Scientific reports 2016;6:31112. doi:
10.1038/srep31112 [published Online First: 2016/08/09]
26. Siristatidis CS, Gibreel A,
Basios G, et al. Gonadotrophin‐releasing hormone agonist protocols for
pituitary suppression in assisted reproduction. Cochrane Database
of Systematic Reviews 2015(11)
27. Al‐Inany HG, Youssef MA, Ayeleke
RO, et al. Gonadotrophin‐releasing hormone antagonists for assisted
reproductive technology. Cochrane Database of Systematic Reviews2016(4)
28. Beguería R, García D, Vassena R,
et al. Medroxyprogesterone acetate versus ganirelix in oocyte donation:
a randomized controlled trial. Human Reproduction2019;34(5):872-80.
29. Roque M, Simon C. Time to
pregnancy: as important for patients as underestimated by doctors.Fertility and sterility 2020;113(3):522-23.
30. Massin N. New stimulation
regimens: endogenous and exogenous progesterone use to block the LH
surge during ovarian stimulation for IVF. Human reproduction
update 2017;23(2):211-20. doi: 10.1093/humupd/dmw047 [published
Online First: 2017/01/08]
31. La Marca A, Capuzzo M. Use of
progestins to inhibit spontaneous ovulation during ovarian stimulation:
the beginning of a new era? Reproductive biomedicine online2019;39(2):321-31.
32. Alexandru P, Cekic SG, Yildiz S,
et al. Progestins versus GnRH analogues for pituitary suppression during
ovarian stimulation for assisted reproductive technology: a systematic
review and meta-analysis. Reproductive biomedicine online2020;40(6):894-903.
33. Evans MB, Parikh T, DeCherney AH,
et al. Evaluation of the cost-effectiveness of ovulation suppression
with progestins compared with GnRH analogs in assisted reproduction
cycles. Reproductive biomedicine online 2019;38(5):691-98.
34. Ata B, Seli E. A universal freeze
all strategy: why it is not warranted. Current Opinion in
Obstetrics and Gynecology 2017;29(3):136-45.
35. Ata B, Capuzzo M, Turkgeldi E, et
al. Progestins for pituitary suppression during ovarian stimulation for
ART: a comprehensive and systematic review including meta-analyses.Human reproduction update 2021;27(1):48-66.